Method for the diagnosis and prognosis of malignant diseases

Abstract

Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.

1 - 17 . (canceled) 
     
     
         18 . A pharmaceutical composition for treating cancer in a subject, comprising a therapeutically effective amount to treat a tumor or cancer of an anti-nucleolin antibody and a pharmaceutically acceptable carrier, wherein the anti-nucleolin antibody is substantially non-immunogenic to human. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the composition is in unit dosage form. 
     
     
         20 . The pharmaceutical composition of  claim 18 , wherein the anti-nucleolin antibody is a monoclonal antibody. 
     
     
         21 . The pharmaceutical composition of  claim 18 , wherein the pharmaceutical composition is an injectable formulation. 
     
     
         22 . The pharmaceutical composition of  claim 18 , wherein the anti-nucleolin antibody is an artificial antibody. 
     
     
         23 . The pharmaceutical composition of  claim 18 , wherein the anti-nucleolin antibody is an antibody fusion protein. 
     
     
         24 . The pharmaceutical composition of  claim 18 , wherein the anti-nucleolin antibody is not an antibody fragment. 
     
     
         25 . The pharmaceutical composition of  claim 18 , wherein the anti-nucleolin antibody is a human antibody. 
     
     
         26 . The pharmaceutical composition of  claim 20 , wherein the anti-nucleolin antibody is a human monoclonal antibody. 
     
     
         27 . A method of treating cancer in a subject comprising:
 administering to said subject a therapeutically effective amount of an anti-nucleolin antibody and a pharmaceutically acceptable carrier, to kill cancer cells,   wherein said nucleolin antibody is substantially non-immunogenic to human.   
     
     
         28 . The method of  claim 27 , further comprising administering to said subject a chemotoxic or chemotherapeutic agent. 
     
     
         29 . The method of  claim 27 , further comprising treating said subject with radiation therapy. 
     
     
         30 . The methods of  claim 28  wherein said chemotoxic or chemotherapeutic agent is selected from the group consisting of cyclophosphamide, etoposide, doxorubicin, methotrexate, vincristine, procabazine, prednisone, dexamethasone, tamoxifen citrate, carboplatin, cisplatin, oxaliplatin, 5-fluorouracil, camptothecin, zoledronic acid, Ibandronate and mytomicin. 
     
     
         31 . The method of  claim 27 , further comprising treating said subject with radiation therapy.